🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

CSDD's Summer 2024 Leadership for Drug Development Teams course is coming up quickly, and in this session, we've introduced focused themes for each day. To learn more about the course and sign up for registration information, visit hubs.ly/Q02tC9p-0

Secure your spot for Tufts CSDD's Summer 2024 Leadership for Drug Development Teams interactive course: hubs.ly/Q02vCKvQ0 To learn more about this year's agenda, please email CSDD Manager of Development and Operations Sarah Wrobel at [email protected]

The May/June 2024 Impact Report: "Use of Digital Endpoints to Collect Clinical Trial Data is Rapidly Increasing" is now available. Explore findings, purchase the report & subscribe to the series at hubs.ly/Q02vzJ7h0

Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development , Tufts School of Medicine and Steve Young, chief science officer, CluePoints discuss what could be holding stakeholders back from adopting risk-based quality management appliedclinicaltrialsonline.com/view/increasin…

Today is Memorial Day in the U.S., a time to honor, remember, and pay tribute to our fallen service members. While dates and traditions differ around the world, gratitude for all those who lost their lives in the line of duty is universal. #MemorialDay #TuftsCSDDRemembers

🌟 On June 3rd, Tufts Center for the Study of Drug Development hosted "New Medicines at a Crossroads," honoring Ken Kaitin. Highlights included a keynote from the FDA's new Office of Clinical Trial Innovation, inspiring panels, and heartfelt tributes. #TuftsCSDD #DrugDevelopment #TuftsMed

TRIAL NEWS 📣: The Partnership for Advancing Clinical Trials (PACT) consortium, in conjunction with Tufts Center for the Study of Drug Development, has produced compelling results from a new study on the effectiveness of decentralized clinical trials (DCTs)🔬. Read more here: medable.com/newsroom/new-r…

To learn more about challenges clinical investigative sites are facing today, Parexel partnered with Tufts Center for the Study of Drug Development on a comprehensive study. The study sheds light on the urgent issues that sponsors and CROs MUST address to minimize site burden. View the key themes below:

To celebrate #Juneteenth, the commemoration of the end of slavery in the United States, Tufts CSDD will be closed tomorrow, June 19th. Join us in honoring an important part of American history and reflecting on the ongoing fight for the equitable treatment of all.

Happy Independence Day to Our U.S.-Based Colleagues 🇺🇸🎆🎉 Tufts CSDD will be closed tomorrow and Friday (July 4th & 5th) to give our team some much-needed R&R.

.Tufts Center for the Study of Drug Development is updating its “cost to make a new drug” analysis! (Once again led by Joe DiMasi.) If your biopharma co wants to contribute data to this effort, read this for details: linkedin.com/pulse/tufts-cs…

In drug development, understanding data sources is crucial. For 45+ years, Tufts CSDD has offered evidence-based industry insights. Join our Circle of Supporters to help us continue. Contact Joan Chambers at [email protected] for details. #ClinicalTrial #Support

Tufts: Toss out the old drug development delay estimates bioworld.com/articles/710666 #biotech #pharma Tufts Center for the Study of Drug Development

Thanks to BioWorld for sharing our Executive Director Ken Getz's insights on drug development delays, also in our latest Impact Report: "Dollar Value of One Day Delay in Drug Development." 🔗 bioworld.com/media/podcasts… To purchase or subscribe, visit csdd.tufts.edu/impact-reports

BioWorld Insider podcast: The costs of delays is updated by Tufts Center for the Study of Drug Development bioworld.com/articles/710712 #biotech #pharma

Lori & guests address clinical trial design, which if done without careful consideration of the patient population can exclude patients from clinical trials instead of being inclusive. hubs.li/Q02LrKPY0 #pharma #biospace Medable | Foley Hoag LLP | Regeneron | Tufts Center for the Study of Drug Development

Happy Labor Day from Tufts CSDD! 🌟 🇺🇸In honor of this day dedicated to the hard work and dedication of our team and all workers, our center will be closed today, Monday, September 2nd. Wishing you all a safe and restful holiday!

Parexel collaborated with Tufts Center for the Study of Drug Development to research the impact of socioeconomic status on access and participation in clinical trials. Click to learn about the survey findings and how socioeconomically vulnerable groups are often excluded from vital research: nature.com/articles/s4385…

Research from the Tufts Center for the Study of Drug Development ’s PACT Consortium shows DCTs encourage higher participation across multiple demographic groups. appliedclinicaltrialsonline.com/view/new-data-…

🚨Our February issue is LIVE🚨 How #centralmonitoring is uncovering emerging quality risks🔺The transformative power of #dataanalytics 🔺The art of saying no🔺and so much more, right here ➡️ appliedclinicaltrialsonline.com/journals/appli…